Author: Jane Griffin

Ossium Health to Present New Clinical Data on Its Organ Donor Bone Marrow at ASH 2025

Posted on December 5, 2025 by - Press Release

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical data at the at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9, 2025 in Orlando, Florida.

Ossium’s key abstract includes clinical data from four patients with hematologic malignancies that were treated with hematopoietic stem cells derived from the vertebral bodies of deceased organ donors. All four patients achieved rapid neutrophil engraftment, platelet recovery, and full donor chimerism. All cases of acute GVHD were successfully managed with steroids and no chronic GVHD was reported. By Day 180, all evaluatable patients were alive and relapse-free. These early results indicate that Ossium’s deceased-donor-derived bone marrow is a promising new graft source that supports robust engraftment while addressing both relapse and GVHD prevention.

The abstract is now available online:

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update
Abstract Number: 5976
Presenter: Sagar Munjal, MD, MS (Chief Medical Officer, Ossium Health)
Date/Time: Monday, December 8, 06:00 PM – 08:00 PM EST
Poster Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III

Ossium’s presence at ASH 2025 underscores the company’s commitment to improving access, speed, and quality in hematopoietic cell transplantation. By presenting new clinical and scientific data and engaging directly with leaders in the hematology community, the company aims to raise awareness to how organ donor bone marrow is driving meaningful therapeutic advantages and overcoming longstanding donor availability limitations.

“We’re excited to share our latest clinical insights with the hematology community at ASH,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Our findings demonstrate the potential of organ donor bone marrow to transform patient outcomes, and we look forward to engaging with clinicians and researchers at our booth.”

In addition to its presentation, Ossium Health will host an exhibit at Booth 112, where attendees can learn more about the company’s organ donor-derived bone marrow and its clinical programs.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

Susannah Cantrell Joins Ossium Health as Chief Commercial Officer

Posted on November 19, 2025 by - Press Release

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a bioengineering company dedicated to improving human health through its organ donor bone marrow banking platform, announced today that Dr. Susannah Cantrell, PhD, has joined its leadership team as Chief Commercial Officer (CCO).

In her new role, Dr. Cantrell will be responsible for leading Ossium’s commercial strategy, go-to-market planning, and partnerships as the company scales its unique platform to meet the needs of the bone marrow transplant field. She will play a critical role in driving the company’s platform from development into full-scale commercial availability.

“Susannah brings a rare combination of commercial leadership, scientific rigor, and operational excellence — exactly what Ossium needs as we advance our platform,” said Kevin Caldwell, Co-Founder & CEO of Ossium Health. “Her track record of building high-performing commercial teams, especially in complex, regulated environments, will be invaluable as we expand adoption of our organ donor bone marrow.”

Dr. Cantrell brings more than two decades of experience in biotechnology and pharmaceuticals. Most recently, she served as Chief Business Officer at Brii Biosciences where she oversaw business development, alliance management, and commercial activities.

Prior to Brii Biosciences, Dr. Cantrell served as Chief Business Officer and Chief Operating Officer at Second Genome, where she oversaw the company’s operations, business development, finance, and facilities. Dr. Cantrell also served as Executive Vice President & Chief Commercial Officer at Tricida, where she built a U.S.-focused commercial organization from the ground up. She held senior leadership roles at Gilead Sciences, including Vice President, Global Commercial Strategy & Marketing – Oncology, where she played a key part in growing Gilead’s oncology and inflammation business lines. Earlier in her career, Dr. Cantrell held various global sales and marketing roles at Genentech/Roche and GlaxoSmithKline.

Dr. Cantrell holds a B.A. in Biology from Westminster College and a Ph.D. in Biochemistry from the University of Missouri-Columbia.

“I am thrilled to join Ossium Health at such an exciting time in its journey,” said Dr. Cantrell. “Their platform has the potential to fundamentally change how we think about cell therapy, and I look forward to working with the team to bring those innovations to patients.”

Her appointment marks a significant step in strengthening Ossium’s leadership as the company prepares for its next phase of growth, advancing commercial readiness and supporting the upcoming launch of its bone marrow at transplant centers nationwide.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

Ossium in the News

Posted on November 22, 2024 by - News

After we reported the first transplant with Ossium’s organ donor bone marrow, several news outlets published stories on this milestone and what it means for the future of stem cell accessibility. Across an array of national, local, and medical news sources, medical experts and journalists chimed in about the significance of this development, calling it a “game changer” (WIRED) and a “historic step forward” (ClickOnDetroit) for the field of stem cell transplantation. 

Links to the stories are below.

National News

WIRED | Bone Marrow Donors Can Be Hard to Find. One Company is Turning to Cadavers

Fox News | Leukemia Patient Receives First-Ever Bone Marrow Transplant from Deceased Organ Donor

Forbes | The Prototype: This Startup Aims to Expand Bone Marrow Availability

The Hustle Daily Show | This Bone Marrow Bank Startup Could Save Lives

Telemundo | Una Mujer es la Primera En Recibir un Trasplante De Médula Ósea de un Paciente Fallecido

Local News (Detroit)

ClickOnDetroit | Michigan Woman One of First in World To Successfully Receive Bone Marrow from Deceased Donor

Detroit Free Press | Flint Woman with Leukemia May Be 1st to get Stem Cell Transplant from Deceased Donor

Kalamazoo Mornings With Ken Lanphear | Gift of Life Michigan President Talks About her Organization’s Role in a Historic Medical Procedure

Medical News

Clinical Trials Arena | Ossium Treats First Leukaemia Patient in Cryopreserved Bone Marrow Trial

Becker’s Hospital Review | Henry Ford Health Patient Among 1st in World to Receive Deceased Donor Bone Marrow Transplant

Ossium Ranks No. 56 on Fast Company’s 100 Best Workplaces for Innovators

Posted on September 12, 2024 by - News

Fast Company announced its sixth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. Ossium came in at No. 56 for its company culture that encourages innovation from every corner of the organization. In addition, Ossium is a finalist on the biotech list.

“We pride ourselves in serving as a top workplace for innovators,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Our business is built on the revolutionary idea of building a vast bone marrow bank that solves a critical infrastructure problem to save thousands of lives. We’ve taken daring steps to turn this bold idea into a reality. As we scale, we continue to benefit from our organizational culture that empowers employees to blaze new trails to help advance our mission.”

The 2024 Best Workplaces for Innovators list ranks 100 winners from a variety of industries, including entertainment, biotech, consumer packaged goods, marketing, education, healthcare, and many more.
“Innovation is a global priority that cuts across all industries, and this year’s list reflects that diversity,” said Brendan Vaughan, editor in chief of Fast Company. “The top ten features four companies headquartered outside of the U.S. and includes representatives from technology, advertising, finance, biotech, pharmaceuticals, ecommerce, and the nonprofit sectors.”

Fast Company’s Best Workplaces for Innovators issue (Fall 2024) is available online now, and the print issue will be on newsstands beginning September 17, 2024. To see the complete list, go to https://www.fastcompany.com/best-workplaces-for-innovators/list.

Ossium is currently searching for innovators to fill open roles at its headquarters in San Francisco and its production facility in Indianapolis. To learn more about these open positions, visit https://ossiumhealth.com/careers/.

First Surgery with OssiGraft Prime Highlights its Exceptional Utility

Posted on July 30, 2024 by - Press Release

Our next-generation viable bone matrix, OssiGraft Prime™, has been released and used in surgery for the first time.

OssiGraft Prime builds upon the success of Ossium’s established OssiGraft™ and incorporates innovative processing advancements. The result is a more cohesive product with a gum-like consistency precisely engineered to meet the demands of orthopedic and spine surgeons. The product’s optimized handling properties enable surgeons to precisely sculpt and apply the graft in the intended location with unprecedented precision and efficiency.

“OssiGraft Prime is by far the best product on the market. I actually said ‘wow!’ out loud in the OR when I handled it in surgery for the first time,” said Dr. Jason Piraino, a leader and educator in foot & ankle surgery. “This product exceeded my expectations. It’s moldable and stays exactly where you want it, which makes it ideal for minimally invasive surgery.”

The first surgery with OssiGraft Prime, an arthroscopic ankle fusion, required the graft to be precisely shaped and placed through a narrow incision, demonstrating the product’s unique value. Surgeons working with OssiGraft Prime benefit from its ability to consistently fill odd-shaped gaps and tight spaces, allowing them to push the boundaries of possibility in orthopedic procedures.

Read the full press release here.

Ossium featured in NYSE Floor Talk

Posted on July 1, 2024 by - News

Ossium CEO Kevin Caldwell recently visited the NYSE and was interviewed on the trading floor.

In Kevin’s conversation with the NYSE’s Judy Shaw, they discussed unmet needs and inequities in the current system for finding bone marrow donors and how Ossium is solving those problems by transforming the process for bone marrow donor acquisition. As Kevin summarizes, “the basic idea is to take these cell therapies that today are both very slow and consequently also very expensive and turn them into a scalable procedure that could ultimately benefit tens of thousands of patients around the world every year.”

The interview wraps up with a discussion of the potential for Ossium to utilize its unique bone marrow banking platform to improve treatments in other fields of medicine.

Check out the full interview below.

Ossium Launches HOPE Program

Posted on May 14, 2024 by - Press Release

Ossium recently introduced a new program that further expands access to Ossium’s bone marrow to patients around the globe. Through the HOPE (HPC Offered for PRESERVE Expansion) Program, patients that need an allogeneic bone marrow transplant but cannot participate in Ossium’s active clinical study (PRESERVE I) have a new opportunity to receive bone marrow from Ossium’s bank.

The goal of Ossium’s PRESERVE trials is to establish organ donor bone marrow as a new source of stem cells for hematologic reconstitution and unlock access to stem cell transplants for the thousands of patients who search unsuccessfully for a donor each year. Ossium launched the HOPE Program after recognizing the sheer volume of patients that need a bone marrow transplant but are unable to participate in the PRESERVE I study due to its eligibility criteria or the patient’s geography.

“Thousands of patients in the US and tens of thousands abroad desperately need a bone marrow transplant but can’t find a donor,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “The HOPE Program is intended to fill that gap.”

For more details, read the press release.

Ossium Health Named to Forbes’ List of America’s Best Startup Employers

Posted on March 15, 2024 by - News

We’re proud to announce that we’ve been named to Forbes’ prestigious list of America’s Best Startup Employers! This recognition places us among the top 500 U.S. startups based on employee satisfaction, reputation, and company growth.

This award reflects our dedication to fostering a work environment that attracts and retains exceptional talent. Ossium employees are driven by the profound impact our work has on individuals battling life-threatening blood and immune diseases. Our team’s unwavering dedication fuels our progress towards our company mission: improving the health, vitality, and longevity of human beings through bioengineering.

See Ossium’s appearance on Forbes’ list of America’s Best Startup Employers here.